Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hassan Alkhateeb

Showing results (31-40 of 87) with videos related to

Pageof 9
Sort By:
Transfusion|January 28, 2026
Chimerism and a framework for clinical practice: A report from the Cellular Therapies Section Coordinating Committee (CTSCC) of Association for Advancement of Blood and Biotherapies (AABB)Indira Guleria, Laura S Connelly-Smith, Asawari Bapat, et al.
American Journal of Hematology|August 4, 2018
The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDSOmar Alkharabsheh, Aref Al-Kali, Salwa Saadeh, et al.
American Journal of Hematology|September 16, 2018
Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromesOmar Alkharabsheh, Salwa S Saadeh, Mrinal S Patnaik, et al.
British Journal of Haematology|May 26, 2022
Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experienceNaseema Gangat, Kristen McCullough, Aref Al-Kali, et al.
Blood Advances|July 23, 2024
Molecular and clinical characterization of ETNK1-mutated myeloid neoplasms: the Mayo Clinic experienceSteven Tessier, Rong He, Patricia Greipp, et al.
Leukemia Research|June 7, 2025
Clinical characteristics and prognostic significance of co-mutated SETBP1/GATA2 myeloid neoplasmsYazan Jabban, Rong He, Kurt Bessonen, et al.
Blood Cancer Journal|November 21, 2020
Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemiaPrateek Pophali, Aasiya Matin, Abhishek A Mangaonkar, et al.
American Journal of Hematology|September 21, 2023
Mast cell cytomorphology and treatment outcome in mast cell leukemiaAyalew Tefferi, Animesh Pardanani, Aref Al-Kali, et al.
Blood Advances|November 21, 2024
T-cell immune cluster analysis using CyTOF identifies unique subgroups of patients with acute myeloid leukemiaTalha Badar, Keith L Knutson, James Foran, et al.
Ejhaem|October 17, 2024
A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B-cell or T-cell acute lymphoblastic leukemia: Results from the ECOG-ACRIN EA9152 protocolNeil D Palmisiano, Ju-Whei Lee, David F Claxton, et al.
Pageof 9

Showing results (31-40 of 87) with videos related to

Sort By:
Pageof 9
Transfusion|January 28, 2026
Chimerism and a framework for clinical practice: A report from the Cellular Therapies Section Coordinating Committee (CTSCC) of Association for Advancement of Blood and Biotherapies (AABB)Indira Guleria, Laura S Connelly-Smith, Asawari Bapat, et al.
American Journal of Hematology|August 4, 2018
The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDSOmar Alkharabsheh, Aref Al-Kali, Salwa Saadeh, et al.
American Journal of Hematology|September 16, 2018
Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromesOmar Alkharabsheh, Salwa S Saadeh, Mrinal S Patnaik, et al.
British Journal of Haematology|May 26, 2022
Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experienceNaseema Gangat, Kristen McCullough, Aref Al-Kali, et al.
Blood Advances|July 23, 2024
Molecular and clinical characterization of ETNK1-mutated myeloid neoplasms: the Mayo Clinic experienceSteven Tessier, Rong He, Patricia Greipp, et al.
Leukemia Research|June 7, 2025
Clinical characteristics and prognostic significance of co-mutated SETBP1/GATA2 myeloid neoplasmsYazan Jabban, Rong He, Kurt Bessonen, et al.
Blood Cancer Journal|November 21, 2020
Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemiaPrateek Pophali, Aasiya Matin, Abhishek A Mangaonkar, et al.
American Journal of Hematology|September 21, 2023
Mast cell cytomorphology and treatment outcome in mast cell leukemiaAyalew Tefferi, Animesh Pardanani, Aref Al-Kali, et al.
Blood Advances|November 21, 2024
T-cell immune cluster analysis using CyTOF identifies unique subgroups of patients with acute myeloid leukemiaTalha Badar, Keith L Knutson, James Foran, et al.
Ejhaem|October 17, 2024
A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B-cell or T-cell acute lymphoblastic leukemia: Results from the ECOG-ACRIN EA9152 protocolNeil D Palmisiano, Ju-Whei Lee, David F Claxton, et al.
Pageof 9